Canada markets closed

Valeo Pharma Inc. (VPH.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.63000.0000 (0.00%)
At close: 02:57PM EST
Full screen
Previous Close0.6300
Open0.6300
Bid0.6300 x N/A
Ask0.6400 x N/A
Day's Range0.6300 - 0.6300
52 Week Range0.4500 - 0.8300
Volume9,000
Avg. Volume39,555
Market Cap51.78M
Beta (5Y Monthly)2.61
PE Ratio (TTM)N/A
EPS (TTM)-0.2800
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.63
  • CNW Group

    VALEO PHARMA ANNOUNCES SENIOR MANAGEMENT CHANGE

    Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Mr. Frederic Fasano has stepped down as Valeo's President and Chief Operating Officer. Mr. Fasano will continue to act as special advisor to the Company and will remain on the Board of Directors. Mr. Fasano's duties and responsibilities are being integrated and assumed by the Company's CEO, Steve Saviuk and its Chief Commercial Officer, Mr. Kyle Steiger.

  • CNW Group

    VALEO PHARMA RAISES Q4 AND FULL YEAR 2022 REVENUE GUIDANCE

    Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company") a Canadian pharmaceutical company, today announced that it has raised revenue guidance for its fourth quarter of 2022 to $12.5 - $13.0 million, an increase of 14% to 18% over previously issued guidance of $11 million. The Company is also increasing its fiscal 2022 revenue guidance to $27.5 – 28.0 million, a forecasted increase exceeding 100% compared to fiscal 2021 revenues of $13.6 million.

  • CNW Group

    VALEO PHARMA ENTERS INTO CANADIAN COMMERCIAL SERVICES AGREEMENT WITH VERU FOR SABIZABULIN IN HOSPITALIZED ADULT PATIENTS WITH COVID-19 AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)

    Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has entered into a Commercial Services Agreement with Veru Inc. (Veru) for sabizabulin for COVID-19 in Canada. Sabizabulin is a novel dual antiviral and anti-inflammatory agent being targeted for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death.